U.S. Bioscience
Executive Summary
U.S. Healthcare subsidiary for cancer drug development files NDA for Hexalen (hexamethylmelamine), an orphan product, for treatment of ovarian cancer. Originally developed by NCI, Hexalen was acquired from Wyeth-Ayerst in exchange for for future royalties. Current standard treatment for ovarian cancer is a combination of cyclophosphamide, Adriamycin and platinum. U.S. Bioscience estimates that about 30,000 patients per year would be candidates for Hexalen therapy ....